Physicians' Academy for Cardiovascular Education

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - Prof. Christoph Wanner - Würzburg, Germany

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - June 25, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK

Familial dysbetalipoproteinemia: Pathofysiology, diagnosis and treatment

10' education - Apr. 11, 2018 - Charlotte Koopal - Utrecht, The Netherlands

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe

What are the key mechanisms of CV benefit of novel diabetes drugs?

10' education - May 1, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar

What is the science driving CVD and T2DM?

10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

Key classes of antidiabetic drugs – How do they work?

10' education - Feb. 14, 2018 - Prof Cliff Bailey - Birmingham, UK - Online CME

Diabetes cardiovascular outcome trials

10' education - Feb. 14, 2018 - Prof. Lawrence Leiter, MD - Toronto, ON, Canada - Online CME

HbA1c in CVD

10' education - Feb. 14, 2018 - Prof Naveed Sattar, MD - University of Glasgow, United Kingdom

Natural history of DM: Focus on micro- and macrovascular complications

10' education - Feb. 13, 2018 - Prof. Kausik Ray, Imperial College Londen, UK - Online CME

Diabetic dyslipidemia and residual risk in the era of LDL control

10' education - Jan. 25, 2018 - Boston, MA, USA - Dr. Aruna Pradhan - Brigham & Women's Hospital, Boston, USA

Diabetes therapies and CVD – Does the ‘how’ matter more than the how much?

10' education - Oct. 27, 2017 - Boston, MA, USA - Dr. Stephen Wiviott - Brigham & Women's Hospital, Boston, USA

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

New therapeutic options can make a difference for diabetic patients with high CV risk

3' education - Aug. 29, 2017 - Prof. John E Deanfield, MD - London, UK

Cardiovascular protection in type 2 diabetes

5' education - Aug. 29, 2017 - Prof. Lars Rydén, cardiologist, Stockholm, Sweden

Insights from the first trials in epigenetics in human: What is the way forward?

10' education - Oct. 20, 2017 - Barcelona, Spain - Stephen Nicholls, MD, Adelaide, Australia - PACE-CME symposium at ESC 2017

Brief update on the LEADER cardiovascular outcomes trial

10' education - Oct. 15, 2017 - Prof. Neil Poulter, cardiologist, London, UK

Management of CV Risk & T2DM: Implications of novel outcome trials

10' education - Aug. 28, 2017 - Barcelona, Spain - John E Deanfield, MD, London, UK - PACE-CME symposium held at ESC 2017

The Clinical Unmet need in the patient with Diabetes and ACS

10' education - Aug. 26, 2017 - Barcelona, Spain - Kausik Ray, MD Imperial College London United Kingdom - PACE-CME symposium held at ESC 2017

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

Molecular mechanisms involved in the beneficial effect of BET inhibition in experimental renal disease

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Marta Ruiz-Ortega – Fundación Jiménez Díaz, Madrid, Spain

The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain

UK: Clinical Dialogues: Lipids & Diabetes 2017

3' education - July 7, 2017 - Stratford Upon Avon, United Kingdom - Prof Peter Sever

How incretin therapy changes diabetes and prediabetes management

3' education - May 22, 2017

Oral GLP-1 receptor agonist reduces HbA1c and body weight in T2DM patients

News - July 12, 2018

In the PIONEER 1 and 3 phase 3a trials, oral semaglutide reduced HbA1c and body weight in T2DM patients compared to placebo or sitagliptin.

Reduced CV risk with intensive blood pressure treatment in T2DM patients on standard glycemic control

Literature - July 11, 2018 - Tsujimoto T and Kajio H. - Hypertension. 2018
In a subanalysis of the ACCORD BP trial, intensive blood pressure treatment in T2DM patients receiving standard glycemic control was significantly associated with a decreased risk of CV events, including HF hospitalization.

In a subanalysis of the ACCORD BP trial, intensive blood pressure treatment in T2DM patients receiving standard glycemic control was significantly associated with a decreased risk of CV events, including HF hospitalization.

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - Prof. Christoph Wanner - Würzburg, Germany
Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.

Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.

Dual GLP-1 and glucagon receptor agonist improves glycemic control and reduces body weight

Literature - July 4, 2018 - Ambery P et al. - Lancet 2018
In a phase 2a study, the dual GLP-1 and glucagon receptor agonist MEDI0382 improved glycemic control and reduced body weight in patients with stable type 2 diabetes who were overweight or obese.

In a phase 2a study, MEDI0382 improved glycemic control and reduced body weight in patients with stable type 2 diabetes who were overweight or obese.

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK
A prespecified analysis of the ODYSSEY OUTCOME trial showed a bigger treatment effect of alirocumab with no adverse effects on measures of glycemia or new onset diabetes in patients with diabetes compared to those with normoglycemia or pre-diabetes.

A prespecified analysis of the ODYSSEY OUTCOME trial showed a bigger treatment effect of alirocumab with no adverse effects on measures of glycemia or new onset diabetes in patients with diabetes compared to those with normoglycemia or pre-diabetes.

Healthy lifestyle after diabetes diagnosis reduces risk of CVD

Literature - July 3, 2018 - Liu G, et al. - J Am Coll Cardiol
Maintaining or changing to a healthy lifestyle after diabetes diagnosis is associated with a significantly lower risk CVD incidence and mortality.

Maintaining or changing to a healthy lifestyle after diabetes diagnosis is associated with a significantly lower risk CVD incidence and mortality.

PCSK9 RNA silencing agent reduces LDL-c in diabetes patients with high CV risk

News - June 27, 2018

A subanalysis of the ORION-1 phase II trial showed that inclisiran reduced LDL-c in high CV risk patients, irrespective of presence of diabetes.

Trials with SGLT2 inhibitor in addition to insulin meet primary efficacy endpoint in type 1 diabetes patients

News - June 26, 2018

In two trials of the EASE phase III program, the primary endpoint of change in HbA1c after 26 week of empagliflozin in addition to insulin was met in type 1 diabetes patients.

No increased risk of below-knee amputation with canagliflozin in real-world study

News - June 25, 2018

ADA 2018 In the OBSERVE-4D real world study, canagliflozin did not result in increased risk of below-knee amputation in T2DM patients or patients with established CVD.

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden
Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

People with ACS and diabetes particularly benefit from PCSK9 inhibitor and statin treatment

News - June 25, 2018

ADA 2018 Analysis of ODYSSEY OUTCOMES trial indicates people with diabetes and prior ACS benefit most from the combination of alirocumab and statins, compared to ACS survivors with prediabetes or with normal glucose levels

Comparison of GLP-1 receptor agonists shows variability in reductions of HbA1c and weight

News - June 25, 2018

In type 2 diabetes patients, semaglutide showed greater reductions of HbA1c and weight compared with liraglutide in the PIONEER 4 trial and compared with sitagliptin in the PIONEER 7 trial.